VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 28.3 %

Shares of VBI Vaccines stock opened at $0.66 on Wednesday. The firm has a market cap of $15.64 million, a PE ratio of -0.06 and a beta of 1.93. The business has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.61. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $5.82.

Institutional Investors Weigh In On VBI Vaccines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP purchased a new position in VBI Vaccines in the 1st quarter valued at $26,000. Alliancebernstein L.P. boosted its stake in VBI Vaccines by 9.9% during the third quarter. Alliancebernstein L.P. now owns 188,900 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 17,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in VBI Vaccines by 8.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 267,148 shares of the biopharmaceutical company’s stock valued at $443,000 after buying an additional 21,587 shares in the last quarter. Voya Investment Management LLC increased its stake in shares of VBI Vaccines by 29.7% in the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 21,824 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in shares of VBI Vaccines by 38.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 100,400 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 27,900 shares during the last quarter. Hedge funds and other institutional investors own 12.26% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.